NCT03191305 (CVT) is a NA clinical trial of Coumadin in Cerebral Venous Thrombosis, sponsored by Foundation University Islamabad.

Who is sponsoring NCT03191305?

NCT03191305 is sponsored by Foundation University Islamabad.

What drugs are being tested in NCT03191305?

Interventions in NCT03191305: Coumadin, Rivoroxaban.

What condition does NCT03191305 study?

NCT03191305 studies Cerebral Venous Thrombosis.

Is NCT03191305 still recruiting?

NCT03191305 is currently status unknown. Last updated 15 June 2017.

Last reviewed 2017-06-15 · How we verify

NCT03191305: CVT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis

Status unknown NA Last updated 15 June 2017

What this trial tests

NA trial testing Coumadin in Cerebral Venous Thrombosis in 50 participants. Status unknown.

Timeline

1 August 2017

Primary endpoint
1 September 2018

1 September 2018

Quick facts

Lead sponsor	Foundation University Islamabad
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	50
Start date	1 August 2017
Primary completion	1 September 2018
Estimated completion	1 September 2018

Drugs / interventions tested

Coumadin (warfarin) — full drug profile →
Rivoroxaban — full drug profile →

Conditions studied

Cerebral Venous Thrombosis — all drugs for Cerebral Venous Thrombosis →

Sponsor

Foundation University Islamabad

Who can join

Adults 13 to 50, any sex, with Cerebral Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hemorrhage or Recurrent CVT based on repeat MRI.
Time frame: 6 months
Outcome measures will include any hemorrhage or recurrent CVT based on repeat MRI.

Sponsor's own description

In past few years new anticoagulants have been developed which directly inhibit thrombin or factor X.factor x inhibitor is available in Pakistan. The superior efficacy of Rivroxaban has been shown in Deep Venous Thrombosis in EINSTEIN study (3).Its definite superiority in prevention of embolic stroke in nonvalvular atrial fibrillation is evidenced by the study ROCKET AF (4). With Rivroxaban no monitoring is required, and also there are no drug interactions .There are few pilot studies of using Rivroxaban in cerebral venous thrombosis. This study is therefore required to find its efficacy in CVT patients as well as its comparison with Coumadin

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol.
Bose G, Graveline J, Yogendrakumar V, Fergusson D, et al · · 2019 · cited 10× · PMID 30999965 · DOI 10.1186/s13643-019-1022-8
Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?
Mathew C, Zumberg M. · · 2021 · cited 3× · PMID 34889369 · DOI 10.1182/hematology.2021000319

Verify or expand the search:

Other recruiting trials for Cerebral Venous Thrombosis

Currently open trials in the same condition.

NCT07352358 — Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis · Phase 4 · recruiting
NCT06947707 — Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients · recruiting
NCT06531122 — Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis · Phase 3 · recruiting

Other Foundation University Islamabad trials

Trials by the same sponsor.

NCT07485777 — Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma · NA · not yet recruiting
NCT07495748 — Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma · NA · not yet recruiting
NCT07519174 — A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% i · NA · not yet recruiting
NCT07526051 — Effects of Autogenic Inhibition Versus Reciprocal Inhibition in Individuals With Lower Cross Syndrome · NA · recruiting
NCT07526012 — Comparative Effects Of Post Isometric Relaxation Versus Active Isolated Stretch In Patients With Piriformis Syndrome · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03191305 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Foundation University Islamabad
Last refreshed: 15 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03191305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing